Plus, news about EXO Biologics:
Centessa prices public offering: The startup aims to raise $93.5 million, or up to $107.6 million if all options are exercised. The funding would extend its runway into mid-2026. On Monday, Centessa announced the FDA cleared the IND for its narcolepsy program, called ORX750. A Phase 1 healthy volunteer study is set to start dosing “imminently,” with data expected in the second half of this year. — Max Gelman
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.